CRDL vs. CMPS, HUMA, MREO, ERAS, ABVX, BNTC, KMDA, PGEN, ITOS, and RVNC
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include COMPASS Pathways (CMPS), Humacyte (HUMA), Mereo BioPharma Group (MREO), Erasca (ERAS), ABIVAX Société Anonyme (ABVX), Benitec Biopharma (BNTC), Kamada (KMDA), Precigen (PGEN), iTeos Therapeutics (ITOS), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical products" industry.
Cardiol Therapeutics vs.
Cardiol Therapeutics (NASDAQ:CRDL) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
COMPASS Pathways received 39 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 82.14% of users gave COMPASS Pathways an outperform vote while only 68.18% of users gave Cardiol Therapeutics an outperform vote.
Cardiol Therapeutics is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
COMPASS Pathways' return on equity of -63.85% beat Cardiol Therapeutics' return on equity.
Cardiol Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500.
In the previous week, Cardiol Therapeutics had 3 more articles in the media than COMPASS Pathways. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 1 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 1.87 beat Cardiol Therapeutics' score of 0.96 indicating that COMPASS Pathways is being referred to more favorably in the news media.
Cardiol Therapeutics presently has a consensus price target of $8.67, indicating a potential upside of 497.70%. COMPASS Pathways has a consensus price target of $18.83, indicating a potential upside of 297.33%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cardiol Therapeutics is more favorable than COMPASS Pathways.
12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
COMPASS Pathways beats Cardiol Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CRDL) was last updated on 6/11/2025 by MarketBeat.com Staff
